Skip to content

MIRA Pharmaceuticals, Inc.

MIRA

$0.61

$-0.18 (-22.49%)

After Hours

Loading chart...

IndexN/A

Market Cap0.03B

Enterprise Value0.03B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-0.42

P/SN/A

P/B3.44

P/C-7.68

EV/EBITDA-2.82

EV/SalesN/A

EPS (ttm)-1.45

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.41M

Shs Outstand0.04B

Change-22.49%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jul 3008:00AMMIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies(globenewswire.com)

Jul 1008:00AMMIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain(accessnewswire.com)

Jul 609:00AMMIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction(accessnewswire.com)

Jun 2508:15AMMIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC(accessnewswire.com)

Jun 1708:00AMMIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy(accessnewswire.com)

Jun 408:00AMMIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1(accessnewswire.com)

May 2708:00AMMIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN(accessnewswire.com)

May 1408:00AMMIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2(accessnewswire.com)

May 1308:00AMMIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate(accessnewswire.com)

May 609:00AMVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains Traction(newsfilecorp.com)

Mar 2309:00AMMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies(accessnewswire.com)

Mar 1809:00AMVisionstate Reports Accelerating Subscription Growth and Expansion of MIRA Compliance Platform(newsfilecorp.com)

Mar 408:00AMMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2(accessnewswire.com)

Mar 301:03AMMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February(defenseworld.net)

Feb 1909:00AMVisionstate Repositions Under MIRA Compliance Platform and Reports Subscription Growth(newsfilecorp.com)

Feb 307:30AMMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study(accessnewswire.com)

Oct 2407:30AMMIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication(accessnewswire.com)

Oct 1607:30AMMIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain(accessnewswire.com)

Sep 3007:30AMMIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction(accessnewswire.com)

Sep 2208:00AMMIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog(accessnewswire.com)

Sep 1607:30AMMIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals(accessnewswire.com)12:30AMMIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals(accessnewswire.com)

Sep 1207:30AMMIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation(accessnewswire.com)

Aug 1908:30AMMIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage(accessnewswire.com)

Aug 1208:30AMMIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin(accessnewswire.com)

Jul 3007:30AMMIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study(accessnewswire.com)

Jul 2907:30AMMIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain(accessnewswire.com)

Jul 1108:00AMMIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition(accessnewswire.com)

Jul 308:00AMMIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks(accessnewswire.com)

Insider Trading

Insider

Type

Shares

Price

Value

Date

Shekhat Denil Nanji

Award

50.0K

$0.94

$47K

Jun 12, 26

MacPherson Edward Clouston

Award

50.0K

$0.94

$47K

Jun 12, 26

Del Giudice Matthew Paul

Award

50.0K

$0.94

$47K

Jun 12, 26

Whalen Matthew Pratt

Award

50.0K

$0.94

$47K

Jun 12, 26

Shekhat Denil Nanji

Award

22.4K

$1.35

$30K

Oct 1, 25

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

CEO: Erez AminovEmployees: 2mirapharmaceuticals.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$8.02M	$8.53M	$7.05M	$2.15M	$67.63K
Operating Income	$-8.02M	$-8.53M	$-7.05M	$-2.15M	$-67.63K
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-7.85M	$-11.98M	$-7.06M	$-2.18M	$-67.99K
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-0.51	$-0.65	$-0.48	$-0.15	$-0.00
EBITDA	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A

Discover more

You may be interested in

Amazon.com Inc

$284.02

JPMorgan Chase & Co

$352.64

Mastercard Inc

$570.97

Walt Disney Co

$98.15

Oracle Corp

$141.90

Visa Inc

$365.67

Netflix Inc

$73.33

Microsoft Corp

$487.65

PayPal Holdings Inc

$57.87

Adobe Inc

$251.34

Alphabet Inc

$373.51

Advanced Micro Devices

$484.64